Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 583

1.

Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad.

Ghany MG, Feld JJ, Chang KM, Chan HLY, Lok ASF, Visvanathan K, Janssen HLA.

Lancet Gastroenterol Hepatol. 2020 Feb 10. pii: S2468-1253(19)30344-9. doi: 10.1016/S2468-1253(19)30344-9. [Epub ahead of print] Review.

PMID:
32057301
2.

Is Sustained Virologic Response to Direct-Acting Antivirals a Valid Surrogate Endpoint for Clinical Outcomes of Hepatitis C?

Lok AS.

Clin Infect Dis. 2020 Feb 13. pii: ciaa147. doi: 10.1093/cid/ciaa147. [Epub ahead of print] No abstract available.

PMID:
32052046
3.

Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B.

Lok AS, Zoulim F, Dusheiko G, Chan HLY, Buti M, Ghany MG, Gaggar A, Yang JC, Wu G, Flaherty JF, Subramanian GM, Locarnini S, Marcellin P.

Hepatol Commun. 2019 Oct 10;4(1):8-20. doi: 10.1002/hep4.1436. eCollection 2020 Jan.

4.

Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)".

Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Reddy KR, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW.

J Hepatol. 2019 Dec 27. pii: S0168-8278(19)30702-0. doi: 10.1016/j.jhep.2019.11.015. [Epub ahead of print] No abstract available.

PMID:
31889556
5.

Fat Accumulation, Liver Fibrosis, and Metabolic Abnormalities in Chinese Patients With Moderate/Severe Versus Mild Hepatic Steatosis.

Zhang W, Huang R, Wang Y, Rao H, Wei L, Su GL, Lok AS.

Hepatol Commun. 2019 Oct 7;3(12):1585-1597. doi: 10.1002/hep4.1435. eCollection 2019 Dec.

6.

A Comparison of Excessive Drinking, Binge Drinking and Alcohol Dependence in Ethnic Minority Groups in the Netherlands: The HELIUS Study.

van Amsterdam JGC, Benschop A, van Binnendijk S, Snijder MB, Lok A, Schene AH, Derks EM, van den Brink W.

Eur Addict Res. 2019 Dec 6:1-11. doi: 10.1159/000504881. [Epub ahead of print]

7.

Long-term deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression.

van der Wal JM, Bergfeld IO, Lok A, Mantione M, Figee M, Notten P, Beute G, Horst F, van den Munckhof P, Schuurman PR, Denys D.

J Neurol Neurosurg Psychiatry. 2020 Feb;91(2):189-195. doi: 10.1136/jnnp-2019-321758. Epub 2019 Dec 4.

8.

Fatty acids and recurrence of major depressive disorder: combined analysis of two Dutch clinical cohorts.

Thesing CS, Lok A, Milaneschi Y, Assies J, Bockting CLH, Figueroa CA, Giltay EJ, Penninx BWJH, Ruhé HG, Schene AH, Bot M, Mocking RJT.

Acta Psychiatr Scand. 2019 Nov 30. doi: 10.1111/acps.13136. [Epub ahead of print]

PMID:
31785112
9.

Ethnic and sex differences in the association of child maltreatment and depressed mood. The HELIUS study.

Sunley AK, Lok A, White MJ, Snijder MB, van Zuiden M, Zantvoord JB, Derks EM.

Child Abuse Negl. 2020 Jan;99:104239. doi: 10.1016/j.chiabu.2019.104239. Epub 2019 Nov 12.

PMID:
31731139
10.

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.

Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty.

J Hepatol. 2019 Nov 12. pii: S0168-8278(19)30671-3. doi: 10.1016/j.jhep.2019.11.003. [Epub ahead of print] Review.

PMID:
31730789
11.

Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference.

Cornberg M, Lok AS, Terrault NA, Zoulim F; 2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty.

Hepatology. 2019 Nov 12. doi: 10.1002/hep.31030. [Epub ahead of print]

PMID:
31713892
12.

Incidence of and Risk Factors for Hepatic Encephalopathy in a Population-Based Cohort of Americans With Cirrhosis.

Tapper EB, Henderson JB, Parikh ND, Ioannou GN, Lok AS.

Hepatol Commun. 2019 Sep 6;3(11):1510-1519. doi: 10.1002/hep4.1425. eCollection 2019 Nov.

13.

Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.

Serper M, Evon DM, Stewart PW, Lok AS, Amador J, Reeve BB, Golin CE, Fried MW, Reddy KR, Sterling RK, Sarkar S, Di Bisceglie AM, Lim JK, Nelson DR, Reau N.

J Gen Intern Med. 2019 Oct 28. doi: 10.1007/s11606-019-05394-9. [Epub ahead of print]

PMID:
31659661
14.

Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia.

Zhou K, Wahed AS, Cooper S, Di Bisceglie AM, Fontana RJ, Ghany MG, Khalili M, Lok AS, Perrillo R, Lee WM, Lau DTY, Sterling R, Janssen HLA, Terrault NA.

Am J Gastroenterol. 2019 Nov;114(11):1753-1763. doi: 10.14309/ajg.0000000000000400.

PMID:
31658127
15.

Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis.

Thomson MJ, Taylor A, Sharma P, Lok AS, Tapper EB.

Dig Dis Sci. 2019 Sep 30. doi: 10.1007/s10620-019-05858-2. [Epub ahead of print]

PMID:
31571102
16.

Prevalence of Viremic Hepatitis C Virus Infection by Age, Race/Ethnicity, and Birthplace and Disease Awareness Among Viremic Persons in the United States, 1999-2016.

Zou B, Yeo YH, Le MH, Henry L, Chang ET, Lok AS, Cheung R, Nguyen MH.

J Infect Dis. 2020 Jan 14;221(3):408-418. doi: 10.1093/infdis/jiz479.

PMID:
31560391
17.

The MYRACLE protocol study: a multicentric observational prospective cohort study of patients with multiple myeloma.

Benaniba L, Tessoulin B, Trudel S, Pellat-Deceunynck C, Amiot M, Minvielle S, Gourraud PA, de Visme S, Maisonneuve H, Lok A, Le Gouill S, Moreau P, Touzeau C.

BMC Cancer. 2019 Aug 29;19(1):855. doi: 10.1186/s12885-019-6080-8.

18.

How Do We Determine Whether a Functional Cure for HBV Infection Has Been Achieved?

Yip TC, Lok AS.

Clin Gastroenterol Hepatol. 2020 Mar;18(3):548-550. doi: 10.1016/j.cgh.2019.08.033. Epub 2019 Aug 22. No abstract available.

PMID:
31446185
19.

Association of a priori dietary patterns with depressive symptoms: a harmonised meta-analysis of observational studies.

Nicolaou M, Colpo M, Vermeulen E, Elstgeest LEM, Cabout M, Gibson-Smith D, Knuppel A, Sini G, Schoenaker DAJM, Mishra GD, Lok A, Penninx BWJH, Bandinelli S, Brunner EJ, Zwinderman AH, Brouwer IA, Visser M.

Psychol Med. 2019 Aug 14:1-12. doi: 10.1017/S0033291719001958. [Epub ahead of print]

PMID:
31409435
20.

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.

Lok AS, Sulkowski MS, Kort JJ, Willner I, Reddy KR, Shiffman ML, Hassan MA, Pearlman BL, Hinestrosa F, Jacobson IM, Morelli G, Peter JA, Vainorius M, Michael LC, Fried MW, Wang GP, Lu W, Larsen L, Nelson DR.

Gastroenterology. 2019 Dec;157(6):1506-1517.e1. doi: 10.1053/j.gastro.2019.08.008. Epub 2019 Aug 8.

PMID:
31401140
21.

Pretreatment cortisol predicts trauma-focused psychotherapy response in youth with (partial) posttraumatic stress disorder.

Zantvoord JB, Ensink JBM, Op den Kelder R, Wessel AMA, Lok A, Lindauer RJL.

Psychoneuroendocrinology. 2019 Nov;109:104380. doi: 10.1016/j.psyneuen.2019.104380. Epub 2019 Jul 17.

22.

Survey of Nonalcoholic Fatty Liver Disease Knowledge, Nutrition, and Physical Activity Patterns Among the General Public in Beijing, China.

Chen S, Chao S, Konerman M, Zhang W, Rao H, Wu E, Lin A, Wei L, Lok AS.

Dig Dis Sci. 2019 Dec;64(12):3480-3488. doi: 10.1007/s10620-019-05709-0. Epub 2019 Jul 4.

PMID:
31273595
23.

Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials.

Likhitsup A, Lok AS.

Clin Liver Dis. 2019 Aug;23(3):401-416. doi: 10.1016/j.cld.2019.04.002. Epub 2019 Jun 1. Review.

PMID:
31266616
24.

Chronic Hepatitis B Prevalence Among Foreign-Born and U.S.-Born Adults in the United States, 1999-2016.

Le MH, Yeo YH, Cheung R, Henry L, Lok AS, Nguyen MH.

Hepatology. 2020 Feb;71(2):431-443. doi: 10.1002/hep.30831. Epub 2019 Aug 13.

PMID:
31228279
25.

'Doctor, why is my baby's arm black?' The neonatal presentation of a Giant Congenital Melanocytic Naevus.

Parmenter KF, Lok A.

Postgrad Med J. 2019 Jul;95(1125):397. doi: 10.1136/postgradmedj-2019-136629. Epub 2019 Jun 13. No abstract available.

PMID:
31196887
26.

Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.

Evon DM, Sarkar S, Amador J, Lok AS, Sterling RK, Stewart PW, Reeve BB, Serper M, Reau N, Rajender Reddy K, Di Bisceglie AM, Nelson DR, Golin CE, Lim JK, Fried MW.

J Hepatol. 2019 Sep;71(3):486-497. doi: 10.1016/j.jhep.2019.04.016. Epub 2019 May 13.

PMID:
31096006
27.

The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers.

Tapper EB, Hao S, Lin M, Mafi JN, McCurdy H, Parikh ND, Lok AS.

Hepatology. 2020 Jan;71(1):225-234. doi: 10.1002/hep.30695. Epub 2019 Jun 21.

PMID:
31063262
28.

FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Cytokine. 2019 Aug;120:85-87. doi: 10.1016/j.cyto.2019.04.015. Epub 2019 Apr 28.

PMID:
31035172
29.

[Reaction on 'Persistant underuse of ECT for persistant depressive disorder?']

Scheepens DS, van Waarde JA, Lok A, Zantvoord JB, de Pont BJHB, Ruhé HG, Denys DAJP, van Wingen GA.

Tijdschr Psychiatr. 2019;61(4):287. Dutch.

30.

Update of the statements on biology and clinical impact of occult hepatitis B virus infection.

Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS; Taormina Workshop on Occult HBV Infection Faculty Members.

J Hepatol. 2019 Aug;71(2):397-408. doi: 10.1016/j.jhep.2019.03.034. Epub 2019 Apr 18. Review.

31.

Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B.

Chang KM, Traum D, Park JJ, Ho S, Ojiro K, Wong DK, Wahed AS, Terrault NA, Khalili M, Sterling RK, Janssen HLA, Shuhart MC, Lau DT, Roberts LR, Johnson GS, Kaplan DE, Betts MR, Lee WM, Lok ASF; Hepatitis B Research Network (HBRN).

PLoS Pathog. 2019 Apr 18;15(4):e1007715. doi: 10.1371/journal.ppat.1007715. eCollection 2019 Apr.

32.

Erratum: Design and rationale of a randomized-controlled trial of home-delivered meals for the management of symptomatic ascites: the SALTYFOOD trial.

Tapper EB, Baki J, Hummel S, Lok A.

Gastroenterol Rep (Oxf). 2019 Apr;7(2):150. doi: 10.1093/gastro/goz017. Epub 2019 Apr 13.

33.

Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.

Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB.

Clin Liver Dis (Hoboken). 2018 Aug 22;12(1):33-34. doi: 10.1002/cld.728. eCollection 2018 Jul. Review. No abstract available.

34.

Design and rationale of a randomized-controlled trial of home-delivered meals for the management of symptomatic ascites: the SALTYFOOD trial.

Tapper EB, Baki J, Hummel S, Lok A.

Gastroenterol Rep (Oxf). 2019 Apr;7(2):146-149. doi: 10.1093/gastro/goz005. Epub 2019 Mar 11. Erratum in: Gastroenterol Rep (Oxf). 2019 Apr;7(2):150.

35.

Management of acute musculoskeletal pain (excluding low back pain): protocol for a systematic review and network meta-analysis of randomised trials.

Busse JW, Craigie S, Sadeghirad B, Couban R, Hong P, Oparin Y, May C, Lok A, Guyatt GH.

BMJ Open. 2019 Apr 3;9(4):e024441. doi: 10.1136/bmjopen-2018-024441.

36.

Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies.

Bouard L, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Duquenne A, Mahe B, Dubruille V, Blin N, Touzeau C, Gastinne T, Le Bris Y, Lok A, Bonnet A, Le Gouill S, Moreau P, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1465-1471. doi: 10.1016/j.bbmt.2019.03.025. Epub 2019 Mar 27.

PMID:
30928627
37.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.

Trudel S, Tessoulin B, Jullien M, Blin N, Gastinne T, Mahé B, Dubruille V, Bonnet A, Lok A, Chevallier P, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Le Gouill S, Moreau P, Touzeau C.

Ann Hematol. 2019 Jun;98(6):1441-1447. doi: 10.1007/s00277-019-03649-3. Epub 2019 Mar 14.

PMID:
30874851
38.

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.

Jullien M, Trudel S, Tessoulin B, Mahé B, Dubruille V, Blin N, Gastinne T, Bonnet A, Lok A, Lebourgeois A, Peterlin P, Garnier A, Chevalier P, Guillaume T, Thomaré P, Le Gouill S, Moreau P, Touzeau C.

Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14.

PMID:
30874850
39.

Reply.

Lok AS, Powderly WG.

Hepatology. 2019 May;69(5):2301. doi: 10.1002/hep.30564.

PMID:
30762891
40.

Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection.

Brahmania M, Lombardero M, Hansen BE, Terrault NA, Lok AS, Perrillo RP, Belle SH, Di Bisceglie AM, Feld JJ, Lee WM, Fried MW, Janssen HLA; Hepatitis B Research Network.

Clin Gastroenterol Hepatol. 2019 Nov;17(12):2541-2551.e2. doi: 10.1016/j.cgh.2019.02.005. Epub 2019 Feb 8.

41.

Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcohol-Associated Cirrhosis.

Mellinger JL, Fernandez A, Shedden K, Winder GS, Fontana RJ, Volk ML, Blow FC, Lok ASF.

Alcohol Clin Exp Res. 2019 Feb;43(2):334-341. doi: 10.1111/acer.13944. Epub 2019 Jan 22.

42.

[Electroconvulsion therapy for persistent depression in the Netherlands; very low application rate].

Scheepens DS, van Waarde JA, Lok A, Zantvoord JB, de Pont BJHB, Ruhé HG, Denys DAJP, van Wingen GA.

Tijdschr Psychiatr. 2019;61(1):16-21. Dutch.

43.

Testing Pediatric Acuity With an iPad: Validation of "Peekaboo Vision" in Malawi and the UK.

Livingstone I, Butler L, Misanjo E, Lok A, Middleton D, Wilson JW, Delfin S, Kayange P, Hamilton R.

Transl Vis Sci Technol. 2018 Jan 9;8(1):8. doi: 10.1167/tvst.8.1.8. eCollection 2019 Jan.

44.

FLT3 ligand plasma levels in acute myeloid leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10. No abstract available.

45.

[Proper patient education improves hepatitis C patients' disease-related knowledge and antiviral treatment acceptance in rural China].

Yang M, Rao HY, Feng B, Wu E, Wei L, Lok AS.

Zhonghua Gan Zang Bing Za Zhi. 2018 Nov 20;26(11):824-828. doi: 10.3760/cma.j.issn.1007-3418.2018.11.004. Chinese.

PMID:
30616316
46.

Frequency and Outcomes of Abnormal Imaging in Patients With Cirrhosis Enrolled in a Hepatocellular Carcinoma Surveillance Program.

Konerman MA, Verma A, Zhao B, Singal AG, Lok AS, Parikh ND.

Liver Transpl. 2019 Mar;25(3):369-379. doi: 10.1002/lt.25398.

PMID:
30582779
47.

The Use and Effects of Electronic Health Tools for Patient Self-Monitoring and Reporting of Outcomes Following Medication Use: Systematic Review.

Lancaster K, Abuzour A, Khaira M, Mathers A, Chan A, Bui V, Lok A, Thabane L, Dolovich L.

J Med Internet Res. 2018 Dec 18;20(12):e294. doi: 10.2196/jmir.9284.

48.

Impact of a structured lifestyle programme on patients with metabolic syndrome complicated by non-alcoholic fatty liver disease.

Konerman MA, Walden P, Joseph M, Jackson EA, Lok AS, Rubenfire M.

Aliment Pharmacol Ther. 2019 Feb;49(3):296-307. doi: 10.1111/apt.15063. Epub 2018 Dec 18.

PMID:
30561027
49.

Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs.

Liu D, Cai T, Lok A, Zheng Y.

J Am Stat Assoc. 2018;113(522):882-892. doi: 10.1080/01621459.2017.1295866. Epub 2017 Feb 28.

50.

Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection.

Feld JJ, Terrault NA, Lin HS, Belle SH, Chung RT, Tsai N, Khalili M, Perrillo R, Cooper SL, Ghany MG, Janssen HLA, Lok AS; Hepatitis B Research Network.

Hepatology. 2019 Jun;69(6):2338-2348. doi: 10.1002/hep.30417. Epub 2019 Mar 14.

PMID:
30549279

Supplemental Content

Support Center